CXR Biosciences® announces the opening of its first USA sales office

In response to the growing North American demand for its investigative toxicology and DMPK services, CXR Biosciences® is pleased to announce the opening of its first USA sales office in Cambridge, MA.

CXR Biosciences® is commercialising innovative approaches to transform the drug development and chemical safety assessment process. As well as introducing new technology platforms, CXR also helps customers to take their candidate compounds through development efficiently, or to resolve problems that have been encountered, through the provision of customized solutions.

Paul Smith, CXR’s Chief Executive Officer, comments:

“The opening of the new CXR office in Boston is an exciting step and a reflection of our continued growth. The US has around 60% of our potential development and this is an area that we envisage being very fruitful for us.”

CXR Biosciences® has business relationships with many of the world’s leading pharmaceutical, chemical and biotechnology companies, as well as academic and research institutions. The company’s head office is located in Dundee, Scotland.

You can contact CXR’s North American sales office directly using the following details:

Tel: +1 617.444.8491
Fax: +1 617.444.8405


245 First Street
Suite 1800
MA 02142

For further information:

CXR Biosciences®
Mr. Paul Smith, CEO
Tel: +44 (0)1382 432 163

CXR Biosciences®
CXR Biosciences® was established in December 2001 by Professor Roland Wolf & Dr. Cliff Elcombe as a spin-out from Dundee University, Scotland and has grown into an established profitable business.  CXR’s collaborative approach, proprietary models and cutting edge expertise have helped customers of all sizes solve issues relating to the selection of drug candidates or safety of compounds.